Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Calidi Biotherapeutics ( (CLDI) ).
On October 22, 2025, Calidi Biotherapeutics announced the formation of a new scientific advisory board aimed at advancing its RedTail platform and progressing CLD-401 into clinical trials. This strategic move is expected to enhance the company’s operational capabilities and strengthen its position in the biotechnology industry.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Average Trading Volume: 504,476
Technical Sentiment Signal: Sell
Current Market Cap: $7.05M
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.